Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment

Arthritis Research and Therapy

Volumn 10, Issue 5, 2008, Pages

  Appel, Heiner ^a   Janssen, Louise ^a   Listing, Joachim ^b   Heydrich, René ^a   Rudwaleit, Martin ^a   Sieper, Joachim ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DESTRUCTION; CARTILAGE DEGENERATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; PROTEIN BLOOD LEVEL; BLOOD; BONE; CARTILAGE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; PATHOLOGY;

ADULT; ALKALINE PHOSPHATASE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BONE AND BONES; CARTILAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56049091470     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2537     Document Type: Article

References (33)

1. Braun J Bollow M Neure L Seipelt E Seyrekbasan F Herbst H Eggens U Distler A Sieper J Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis Arthritis Rheum 1995, 38:499-505. 10.1002/art.1780380407 7718003
2. Braun J Brandt J Listing J Zink A Alten R Golder W Gromnica-Ihle E Kellner H Krause A Schneider M Sörensen H Zeidler H Thriene W Sieper J Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial Lancet 2002, 359:1187-1193. 10.1016/S0140-6736(02)08215-6 11955536
3. Davis JC Jr Heijde Van Der D Braun J Dougados M Cush J Clegg DO Kivitz A Fleischmann R Inman R Tsuji W Enbrel Ankylosing Spondylitis Study Group Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial Arthritis Rheum 2003, 48:3230-3236. 10.1002/art.11325 14613288
4. Heijde van der D Kivitz A Schiff MH Sieper J Dijkmans BA Braun J Dougados M Reveille JD Wong RL Kupper H Davis JC Jr ATLAS Study Group Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 2006, 54:2136-2146. 10.1002/ art.21913 16802350
5. Braun J Landewe R Hermann KG Han J Yan S Williamson P Heijde van der D ASSERT Study Group Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study Arthritis Rheum 2006, 54:1646-1652. 10.1002/ art.21790 16646033
6. Cruickshank B Pathology of ankylosing spondylitis Clin Orthop Relat Res 1971, 74:43-58. 10.1097/00003086-197101000-00007 5540406
7. Bywaters EGL Olsen E Clinicopathological conference. A case of early ankylosing spondylitis with fatal secondary amyloidosis Br Med J 1968, 2:412-416. 1985986 5649004
8. Appel H Kuhne M Spiekermann S Kohler D Zacher J Stein H Sieper J Loddenkemper C Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone-cartilage interface and subchondral bone marrow Arthritis Rheum 2006, 54:1805-1813. 10.1002/ art.21907 16736521
9. Francois RJ Gardner DL Degrave EJ Bywaters EG Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis Arthritis Rheum 2000, 43:2011-2024. 10.1002/ 1529-0131(200009)43:9<2011::AID-ANR12>3.0.CO;2-Y 11014351
10. Savill DL The manubrio-sternal joint in ankylosing spondylitis J Bone Joint Surg Br 1951, 33:56-64. 14814161
11. Appel H Kuhne M Spiekermann S Ebhardt H Groszdanovic Z Köhler D Dreimann M Hempfing A Rudwaleit M Stein H Metz-Stavenhagen P Sieper J Loddenkemper C Immunohistological analysis of zygapophyseal joints in patients with ankylosing spondylitis Arthritis Rheum 2006, 54:2845-2851. 10.1002/art.22060 16947385
12. Appel H Loddenkemper C Kuhne M Spiekermann S Ebhardt H Grozdanovic Z Köhler D Dreimann M Hempfing A Metz-Stavenhagen P Rudwaleit M Sieper J Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis Arthritis Res Ther 2006, 8:R143. 1779434 16925803 10.1186/ar2035
13. Jain RK Molecular regulation of vessel maturation Nat Med 2003, 9:685-693. 10.1038/nm0603-685 12778167
14. Drouart M Saas P Billot M Cedoz JP Tiberghien P Wendling D Toussirot E High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies Clin Exp Immunol 2003, 132:158-162. 1808664 12653851 10.1046/j.1365-2249.2003.02101.x
15. Murphy G Knäuper V Atkinson S Butler G English W Hutton M Stracke J Clark I Matrix metalloproteinases in arthritic disease Arthritis Res 2002, 4(Suppl 3):S39-S49. 12110122 10.1186/ar572
16. Zhu J Yu DT Matrix metalloproteinase expression in the spondyloarthropathies Curr Opin Rheumatol 2006, 18:364-368. 10.1097/ 01.bor.0000231904.04548.09 16763456
17. Chen CH Lin KC Yu DT Yang C Huang F Chen HA Liang TH Liao HT Tsai CY Wei JC Chou CT Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity Rheumatology (Oxford) 2006, 45:414-420. 10.1093/rheumatology/kei208 16287916
18. Maksymowych WP Poole AR Hiebert L Webb A Ionescu M Lobanok T King L Davis JC Jr Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis J Rheumatol 2005, 32:1911-1917. 16206346
19. Maksymowych WP Landewé R Conner-Spady B Dougados M Mielants H Tempel van der H Poole AR Wang N Heijde van der D Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis Arthritis Rheum 2007, 56:1846-1853. 10.1002/art.22589 17530713
20. Weaver CM Peacock M Martin BR McCabe GP Zhao J Smith DL Wastney ME Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females J Bone Miner Res 1997, 12:1714-1720. 10.1359/jbmr.1997.12.10.1714 9333133
21. Rudwaleit M Khan MA Sieper J The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria? Arthritis Rheum 2005, 52:1000-1008. 10.1002/art.20990 15818678
22. Haibel H Rudwaleit M Listing J Heldmann F Wong RL Kupper H Braun J Sieper J Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two Arthritis Rheum 2008, 58:1981-1991. 10.1002/art.23606 18576337
23. Haibel H Rudwaleit M Brandt HC Grozdanovic Z Listing J Kupper H Braun J Sieper J Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial Arthritis Rheum 2006, 54:678-681. 10.1002/art.21563 16447247
24. Visvanathan S Wagner CL Marini JC Heijde van der D Baker D Gathany T Han J Braun J Inflammatory biomarkers, disease activity, and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab Ann Rheum Dis 2008, 67:511-517. 2564765 17644552 10.1136/ ard.2007.071605
25. Visvanathan S Heijde van der D Deodhar A Wagner C Baker DG Han J Braun J Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis Ann Rheum Dis
26. Woo JH Lee HJ Sung IH Kim TH Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept J Rheumatol 2007, 34:1753-1759. 17610317
27. Yang C Gu J Rihl M Baeten D Huang F Zhao M Zhang H Maksymowych WP De Keyser F Veys EM Yu DT Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis Arthritis Rheum 2004, 51:691-699. 10.1002/ art.20696 15478146
28. Mitra D Elvins DM Collins AJ Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures J Rheumatol 1999, 26:2201-2204. 10529140
29. Vandooren B Kruithof E Yu DT Rihl M Gu J De Rycke L Bosch Van Den F Veys EM De Keyser F Baeten D Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy Arthritis Rheum 2004, 50:2942-2953. 10.1002/art.20477 15457463
30. Sieper J Appel H Braun J Rudwaleit M Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes Arthritis Rheum 2008, 58:649-656. 10.1002/art.23260 18311819
31. Briot K Garnero P Gossec L Charni N Kolta S Dougados M Roux C Etanercept has beneficial effects on bone and cartilage metabolism in patients with ankylosing spondylitis [abstract] Arthritis Rheum 2006, 59:s718.
32. Allali F Breban M Porcher R Maillefert JF Dougados M Roux C Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha Ann Rheum Dis 2003, 62:347-349. 1754495 12634235 10.1136/ard.62.4.347
33. Linden van der SM Valkenburg HA de Jongh BM Cats A The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population Arthritis Rheum 1984, 27:241-249. 10.1002/art.1780270301 6608352